Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study

Cancer Management and Research
Zhichao TianJiaqiang Wang

Abstract

Programmed cell death 1 (PD-1) inhibitors are ineffective as monotherapy for the treatment of soft tissue sarcomas (STS). However, increasing evidence shows that the combination of PD-1 inhibitors and chemotherapy is efficacious and safe for many types of malignancies, including STS. This study aimed to assess the safety and efficacy of doxorubicin chemotherapy plus PD-1 inhibitor in the treatment of metastatic STS. We retrospectively reviewed 21 patients with metastatic STS who received doxorubicin chemotherapy plus a PD-1 inhibitor between November 2017 and October 2018. The objective response rate was 47.6%, the disease control rate was 71.40%, and the median progression-free survival was 6 months (95% CI, 2-8 months). The average change in target lesion diameter from baseline was -25.15 ± 41.61. Majority of the patients experienced grade 1/2 adverse events (AEs), the grade 3/4 AEs were few. The most common grade 3/4 AEs were as follows: leukopenia (23.8%) and anemia (19.0%). Immune-related AEs were common and included hypothyroidism (14.3%) and pneumonitiss (9.5%). No drug related deaths occurred. This study provides preliminary evidence that the combination of doxorubicin chemotherapy and PD-1 inhibitor for advanced STS is...Continue Reading

References

Jan 21, 2011·Cancer Metastasis Reviews·Oliver KeppGuido Kroemer
Mar 13, 2014·The Lancet Oncology·Ian JudsonUNKNOWN European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Dec 19, 2015·Cancer Cell·Lorenzo GalluzziGuido Kroemer
Apr 19, 2016·Zhonghua zhong liu za zhi [Chinese journal of oncology]·UNKNOWN Sarcoma Committee of Chinese Anti-Cancer Association, UNKNOWN Chinese Society of Clinical Oncology
Aug 11, 2017·Therapeutic Advances in Medical Oncology·Gino K InWilliam W Tseng
Aug 15, 2017·Journal of Drug Targeting·Juan LiRongmei Wang
Jan 22, 2018·Pharmacology & Therapeutics·Matthen MathewNaiyer A Rizvi
Feb 13, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·UNKNOWN Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Apr 18, 2018·Therapeutic Advances in Medical Oncology·Chiara LazzariVanesa Gregorc
May 13, 2018·Journal of the National Comprehensive Cancer Network : JNCCN·Margaret von MehrenJillian L Scavone
Aug 24, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hossein BorghaeiLeena Gandhi
Jan 9, 2019·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 26, 2019·Drugs·Susan J Keam
Jul 18, 2019·Drugs·Anthony Markham, Susan J Keam
Nov 7, 2019·OncoTargets and Therapy·Wenli Zuo, Lingdi Zhao

❮ Previous
Next ❯

Citations

Aug 9, 2020·Expert Review of Gastroenterology & Hepatology·Zhongguang ChenKelly Koral
Jan 25, 2021·QJM : Monthly Journal of the Association of Physicians·Mauro VasellaBong-Sung Kim

❮ Previous
Next ❯

Software Mentioned

GraphPad Prism

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

© 2021 Meta ULC. All rights reserved